Tissue microarrays were constructed that allowed analysis of @ patients randomly assigned to receive chemotherapy alone ( Arm A ) , sequential trastuzumab after chemotherapy ( Arm B ) and chemotherapy with concurrent trastuzumab ( Arm C ) .